P/B
—
Atara Biotherapeutics
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
$95.5M
Market Cap • 9/11/2026
2012
(14 years)
Founded
2014
(12 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
15,4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
95,5M
EV
94,4M
EV/Revenue
15,2
EV/EBITDA
-6,7
EV/EBIT
-6,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-9,2%
Total Yield
-9,2%
Payout
0%
Retained Earnings
-2B
Profitability
Gross Margin
91,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
68%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
32%
% Goodwill
0%
ROE
46,3%
ROIC
—
Growth
CAGR Revenue 5Y
-3,6%
CAGR Op. Income 5Y
-46,3%
CAGR Net Income 5Y
-44,5%
CAGR EPS 5Y
-57,3%
CAGR OCF 5Y
-34,7%
Leverage
N.D./EBITDA
0,1
Debt/Equity
0%
Current Ratio
2
Quick Ratio
1,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!